A6 Secondary Metabolites · Dibenzofuran · Benchmark compound · Research use only

Usnic Acid Benchmark Line

The standard reference metabolite for benchmarking cytotoxicity and antioxidant assays, and a control compound in multi-metabolite panels. Supplied for research use only — significant toxicological caution is required before any consumer positioning.

Book a 30-minute discovery call Request the data package

Evidence: Peer-reviewed 2022 (comparative)
Stage: Pilot-ready · RUO material
Indicative: € 3 000 – 18 000negotiable by scope and application

Toxicological caution. Usnic acid is supplied for laboratory research use only. It requires significant toxicological assessment before any consumer, cosmetic, food or therapeutic positioning is even considered. We will not support a consumer-facing application of this compound without that assessment.

Scientific summary

Usnic acid is the standard reference metabolite in lichen chemistry. In our 2022 comparative study it was included as a synthetic reference compound alongside the isolated natural metabolites, giving a directly comparable measurement inside the same assay system.

Why keep a benchmark in the panel

A benchmark compound with a large external literature lets you position your own results against published work and verify that an assay is behaving. That is its role here — a control, not a product candidate.

Applications

Benchmark in cytotoxicity assays
Benchmark in antioxidant assays
Control compound in multi-metabolite panels
Method validation

Assays & readouts available

DPPH and superoxide scavenging
Cell viability
Comparative panel positioning

Specification

Compound class	Dibenzofuran (lichen secondary metabolite)
Evidence status	Published comparative evidence (in vitro) · research use only
Publication	Elečko J et al., Plants 2022;11(8):1077
Typical pilot	Included as control within a bioactivity pilot
Deliverables	Benchmark material, comparative data, technical report
Engagement	Feasibility scan · pilot
Indicative price	€ 3 000 – 18 000, negotiable by scope and application

What happens next

Book a call or send an inquiry. Tell us the target, the application and the timeline.
We answer within three working days — including when the answer is that we cannot help.
NDA before disclosure, if you need one. Tick the box on the form.
Feasibility scan or pilot proposal with a defined scope, deliverable and price.

Book a 30-minute discovery call Send an inquiry

Common questions

How does an engagement start?

With a free 30-minute discovery call. We establish whether there is a fit and what the right next step is. Nothing is committed at that point.

Can we sign an NDA before we describe our project?

Yes. Tick the NDA box on the inquiry form and we arrange it before any disclosure.

Are the prices on this site binding?

No. They are indicative ranges so that you can size a project before contacting us. Final terms are negotiated per scope.

How quickly do you reply?

Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

What happens if you cannot help?

We say so, early, and where we can we point you to someone who can. A negative feasibility answer delivered quickly is a useful result.

Related in Secondary Metabolites

A1Lead compound

Depside · Umbilicaria hirsuta

Gyrophoric Acid Platform

The best-characterised compound in the portfolio. Published work reports ROS production, apoptosis and modulation of Akt, Erk1/2 and p38 MAPK in HeLa cells, with a validated isolation protocol giving high-purity material.

Evidence: Peer-reviewed 2019 · mechanistic dataset
Stage: Pilot-ready · licensing open
Indicative: € 8 000 – 35 000negotiable by scope and application

View details Discuss this

Depsidone · Hypogymnia physodes

3-Hydroxyphysodic Acid Antioxidant Line

The strongest radical scavenger in our comparative metabolite study — and the comparison was made per mole rather than per unit weight. That distinction matters when you translate a screening result into a formulation dose.

Evidence: Peer-reviewed 2022 · DPPH + superoxide
Stage: Pilot-ready · licensing open
Indicative: € 5 000 – 25 000negotiable by scope and application

View details Discuss this

Depside · Reference metabolite

Atranorin Bioactivity Line

A widely cited lichen compound with repeatedly published bioactivity, included in both of our screening studies. A dependable reference compound and panel anchor for antiproliferative, antioxidant and antimicrobial work.

Evidence: Peer-reviewed 2022 & 2023
Stage: Pilot-ready · licensing open
Indicative: € 4 000 – 22 000negotiable by scope and application

View details Discuss this

Tell us what you are trying to achieve.

A free 30-minute call establishes whether there is a fit and what the right next step is. Every inquiry is acknowledged within one working day and answered by the responsible group leader within three.

Book a 30-minute discovery call Send an inquiry instead